Sp1-Dependent Regulation of PPARα in Bone Metabolism

International Journal of Oral and Maxillofacial Implants

Volumn 29, Issue 1, 2014, Pages e107-e116

  Duttenhoefer, Fabian ^a,b   Biswas, Subrata K ^c   Igwe, John C ^d   Sauerbier, Sebastian ^a   Bierhaus, Angelika ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY   (Bangladesh)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

bone tissue engineering; in ammation; NF B; osteoblast; PPAR ; Sp1

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1;

ANIMAL; ARTICLE; BINDING SITE; C57BL MOUSE; GENE DELETION; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MOUSE; OSTEOBLAST; OSTEOLYSIS; PHYSIOLOGY; PROMOTER REGION;

ANIMALS; BINDING SITES; BONE RESORPTION; GENE EXPRESSION; HUMANS; MICE; MICE, INBRED C57BL; NF-KAPPA B; OSTEOBLASTS; PPAR ALPHA; PROMOTER REGIONS, GENETIC; SEQUENCE DELETION; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84900031462     PISSN: 08822786     EISSN: 19424434     Source Type: Journal    
DOI: 10.11607/jomi.te49     Document Type: Article

References (45)

1. 1. Kolar P, Schmidt-Bleek K, Schell H, et al. The early fracture hematoma and its potential role in fracture healing. Tissue Eng Part B Rev 2010;16:427–434.
2. 2. Pape H-C, Marcucio R, Humphrey C, Colnot C, Knobe M, Harvey EJ. Trauma-induced inflammation and fracture healing. J Orthop Trauma 2010;24:522–525.
3. 3. Franke S, Rüster C, Pester J, Hofmann G, Oelzner P, Wolf G. Advanced glycation end products affect growth and function of osteoblasts. Clin Exp Rheumatol 2011;29:650–660.
4. 4. Mountziaris PM, Spicer PP, Kasper FK, Mikos AG. Harnessing and modulating inflammation in strategies for bone regeneration. Tissue Eng Part B Rev 2011;17:393–402.
5. 5. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347(6294):645–650.
6. 6. Lee C-H, Olson P, Evans RM. Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003;144:2201–2207.
7. 7. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996;384:39–43.
8. 8. Mouthiers A, Baillet A, Deloménie C, Porquet D, Mejdoubi-Charef N. Peroxisome proliferator-activated receptor alpha physically interacts with CCAAT/enhancer binding protein (C/ EBPbeta) to inhibit C/EBPbeta-responsive alpha1-acid glyco-protein gene expression. Mol Endocrinol 2005;19:1135–1146.
9. 9. Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998;273:25573–25580.
10. 10. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998;393:790–793.
11. 11. Takano M, Otsuka F, Matsumoto Y, et al. Peroxisome proliferator-activated receptor activity is involved in the osteoblastic differentiation regulated by bone morphogenetic proteins and tumor necrosis factor-α. Mol Cell Endocrinol 2012;348:224–232.
12. 12. Dahdaleh FS, Carr JC, Calva D, Howe JR. SP1 regulates the transcription of BMPR1A. J Surg Res 2011;171:e15–e20.
13. 13. Ji C, Casinghino S, McCarthy TL, Centrella M. Multiple and essential Sp1 binding sites in the promoter for transforming growth factor-beta type I receptor. J Biol Chem 1997;272: 21260–21267.
14. 14. Neish AS, Khachigian LM, Park A, Baichwal VR, Collins T. Sp1 is a component of the cytokine-inducible enhancer in the promoter of vascular cell adhesion molecule-1. J Biol Chem 1995;270:28903–28909.
15. 15. Xu XM, Tang JL, Chen X, Wang LH, Wu KK. Involvement of two Sp1 elements in basal endothelial prostaglandin H synthase-1 promoter activity. J Biol Chem 1997;272:6943–6950.
16. 16. Safe S, Kim K. Nuclear receptor-mediated transactivation through interaction with Sp proteins. Prog Nucleic Acid Res Mol Biol 2004;77:1–36.
17. 17. Kliewer SA, Forman BM, Blumberg B, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 1994;91:7355–7359.
18. 18. Mounier C, Posner BI. Transcriptional regulation by insulin: From the receptor to the gene. Can J Physiol Pharmacol 2006; 84:713–724.
19. 19. Quandt K, Frech K, Karas H, Wingender E, Werner T. MatInd and MatInspector: New fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995;23:4878–4884.
20. 20. Gearing KL, Crickmore A, Gustafsson JA. Structure of the mouse peroxisome proliferator activated receptor alpha gene. Biochem Biophys Res Commun 1994;199:255–263.
21. 21. Xu J, Chavis JA, Racke MK, Drew PD. Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol 2006;176:95–105.
22. 22. Bakker A, Klein-Nulend J. Osteoblast isolation from murine calvariae and long bones. Methods Mol Med 2003;80:19–28.
23. 23. Bierhaus A, Schiekofer S, Schwaninger M, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001;50:2792–2808.
24. 24. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156–159.
25. 25. Birnboim HC, Doly J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res 1979;7:1513–1523.
26. 26. Mackman N, Morrissey JH, Fowler B, Edgington TS. Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade. Biochemistry 1989;28:1755–1762.
27. 27. Bierhaus A, Chevion S, Chevion M, et al. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997;46:1481–1490.
28. 28. Jain VK, Magrath IT. A chemiluminescent assay for quantitation of beta-galactosidase in the femtogram range: Application to quantitation of beta-galactosidase in lacZ-transfected cells. Anal Biochem 1991;199:119–124.
29. 29. Pineda Torra I, Jamshidi Y, Flavell DM, Fruchert JC, Staels B. Characterization of the human PPARalpha promoter: Identification of a functional nuclear receptor response element. Mol Endocrinol 2002;16:1013–1028.
30. 30. Brown JD, Plutzky J. Peroxisome proliferator activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007;115:518–533.
31. 31. Daynes RA, Jones DC. Emerging roles of ppars in inflammation and immunity. Nat Rev Immunol 2002;2:748–759.
32. 32. Genolet R, Wahli W, Michalik L. PPARs as drug targets to modulate inflammatory responses? Curr Drug Targets Inflamm Allergy 2004;3:361–375.
33. 33. Rizzo G, Fiorucci S. PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol 2006;6:421–427.
34. 34. Muoio DM, Newgard CB. Obesity-related derangements in metabolic regulation. Annu Rev Biochem 2006;75:367–401.
35. 35. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411: 494–498.
36. 36. Reynders V, Loitsch S, Steinhauer C, Wagner T, Steinhilber D, Bargon J. Peroxisome proliferator-activated receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes. Respir Res 2006;7:104.
37. 37. Caelles C, González-Sancho JM, Muñoz A. Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev 1997;11:3351–3364.
38. 38. Rogatsky I, Logan SK, Garabedian MJ. Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. Proc Natl Acad Sci USA 1998;95: 2050–2055.
39. 39. Delerive P, De Bosscher K, Besnard S, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999;274:32048–32054.
40. 40. Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HMG, Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood 2003;101:545–551.
41. 41. Delerive P. Induction of Ikappa Balpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 2000;275:36703–36707.
42. 42. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999;99:3125–3131.
43. 43. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998; 273:32833–32841.
44. 44. Chinetti G, Fruchart J-C, Staels B. Peroxisome proliferator-activated receptors: New targets for the pharmacological modulation of macrophage gene expression and function. Curr Opin Lipidol 2003;14:459–468.
45. 45. Standage SW, Caldwell CC, Zingarelli B, Wong HR. Reduced peroxisome proliferator-activated receptor α expression is associated with decreased survival and increased tissue bacterial load in sepsis. Shock 2012;37:164–169.